Caris Life Sciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Termination of Amended and Restated Investors’ Rights Agreement
Effective August 4, 2026, the Company entered into a Termination Agreement (the “Termination Agreement”) with certain of its shareholders, pursuant to which the Company’s Amended and Restated Investors’ Rights Agreement, dated as of April 1, 2025, by and among the Company and the investors party thereto (the “Investors’ Rights Agreement”), was terminated in its entirety and is of no further force or effect, other than certain limited indemnification provisions that survive termination. The Investors’ Rights Agreement previously provided the shareholders party thereto with registration rights.
The Investors’ Rights Agreement is filed as Exhibit 4.3 to our Annual Report on Form 10-K for the year ended December 31, 2025.
Disclosure of Trading Arrangements
During the fiscal quarter ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.